Loading…
Artiva Biotherapeutics, Inc. is projected to rise to $14.74 by 2027, a +46% move from its current price of $10.10. ARTV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $9.69 | $10.11 | $10.55 | +0.08% |
| Aug 4 | $9.53 | $10.12 | $10.74 | +0.15% |
| Aug 5 | $9.41 | $10.12 | $10.90 | +0.23% |
| Aug 6 | $9.31 | $10.13 | $11.03 | +0.31% |
| Aug 7 | $9.22 | $10.14 | $11.15 | +0.38% |
| Aug 8 | $9.14 | $10.15 | $11.26 | +0.46% |
| Aug 9 | $9.07 | $10.15 | $11.36 | +0.54% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.07 | $10.15 | $11.36 | +0.54% |
| Week 2 | $8.71 | $10.21 | $11.97 | +1.07% |
| Week 3 | $8.45 | $10.26 | $12.47 | +1.62% |
| Week 4 | $8.24 | $10.32 | $12.92 | +2.16% |
| Week 5 | $8.07 | $10.37 | $13.34 | +2.71% |
| Week 6 | $7.92 | $10.43 | $13.73 | +3.26% |
| Week 7 | $7.79 | $10.48 | $14.12 | +3.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Artiva Biotherapeutics, Inc. trades under the symbol ARTV. The current price is $10.32 with a market capitalization of $501.43M, ranking 2895 by market cap among listed companies. The stock is categorized in Healthcare. The price outlook is bullish over the multi-year horizon, with a path that shows meaningful upside through 2030 and beyond.
A major floor 50.4% below — a decisive break under it would weaken the trend.
The nearest floor, 12.6% below — buyers have tended to step in here.
The nearest ceiling, 4.3% above — a clean break opens room to run.
A major ceiling 32.6% above — clearing it would confirm fresh momentum.
Key ARTV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARTV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.28 | Sell | $10.19 | Sell |
| MA 10 | $10.07 | Buy | $10.07 | Buy |
| MA 20 | $9.75 | Buy | $9.83 | Buy |
| MA 50 | $8.94 | Buy | $9.34 | Buy |
| MA 100 | $8.72 | Buy | $8.49 | Buy |
| MA 200 | $6.48 | Buy | $7.24 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.07 | Neutral |
| Stoch RSI (14) | 49.01 | Neutral |
| CCI (20) | 58.18 | Neutral |
| Williams %R (14) | -28.86 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 1.81 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 71.14 | Neutral |
| TRIX (15) | 0.44 | Buy |
| Awesome (5,34) | 0.66 | Buy |
| Ultimate (7,14,28) | 54.46 | Neutral |
| Momentum (10) | 0.34 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 10.31 | Sell |
| ADX (14) | 11.66 | Neutral |
| ATR (14) | 0.38 | Info |
The near-term technical picture is bullish. RSI(14) is 60, with the 50-day simple moving average at $8.89 and the 200-day simple moving average at $6.30, indicating positive momentum. The stock appears to be around the resistance level at $10.32, with support near $8.00. The 30-day price range spans from $7.60 to $14.01, reflecting near-term volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.74 | $10.10 | $15.37 | 0% | Neutral | |
| $11.16 | $14.74 | $20.90 | +46% | Bullish | |
| $15.57 | $21.54 | $32.24 | +113% | Bullish | |
| $17.45 | $25.11 | $39.18 | +149% | Bullish | |
| $17.04 | $25.39 | $41.01 | +151% | Bullish | |
| $18.65 | $28.71 | $47.78 | +184% | Bullish | |
| $19.43 | $30.84 | $52.70 | +205% | Bullish | |
| $20.64 | $33.72 | $59.00 | +234% | Bullish | |
| $24.69 | $41.48 | $74.17 | +311% | Bullish | |
| $30.52 | $52.68 | $96.10 | +422% | Bullish | |
| $34.22 | $67.06 | $132.91 | +564% | Bullish | |
| $86.66 | $192.58 | $429.41 | +18.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.74 | $10.10 | $13.32 | +0.00% |
| September 2026 | $9.33 | $11.22 | $14.00 | +11.07% |
| October 2026 | $8.91 | $10.83 | $13.73 | -3.47% |
| November 2026 | $9.02 | $11.06 | $14.21 | +2.14% |
| December 2026 | $9.56 | $11.82 | $15.37 | +6.88% |
Click any year to see its month-by-month ARTV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ARTV is projected to trade between $3.74 and $15.37, averaging $10.10 — a potential gain of 0% from today's $10.10. Price action looks broadly range-bound.
Artiva Biotherapeutics, Inc.'s 2027 outlook centres on $14.74, within a $11.16 to $20.90 range. That is up +46% on the projected 2026 average. That marks a +46% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, ARTV could reach as high as $32.24, with a base case around $21.54 and support toward $15.57 — roughly +113% from $10.10. Momentum favours further upside here.
Expect ARTV to range from $17.45 to $39.18 through 2029. The $25.11 average target implies a +149% move from current prices. That is up +17% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The ARTV price prediction for 2030 points to an average of $25.39 (low $17.04, high $41.01) — a potential gain of +151% on today's $10.10. Momentum favours further upside here.
In 2031, ARTV is projected to trade between $18.65 and $47.78, averaging $28.71 — a potential gain of +184% from today's $10.10. That is up +13% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Artiva Biotherapeutics, Inc.'s 2032 outlook centres on $30.84, within a $19.43 to $52.70 range. That is up +7% on the projected 2031 average. That marks a +205% change versus current levels. Momentum favours further upside here.
By 2033, ARTV could reach as high as $59.00, with a base case around $33.72 and support toward $20.64 — roughly +234% from $10.10. Buyers look set to stay in control over this stretch.
Expect ARTV to range from $24.69 to $74.17 through 2034. The $41.48 average target implies a +311% move from current prices. That is up +23% on the projected 2033 average. Momentum favours further upside here.
The ARTV price prediction for 2035 points to an average of $52.68 (low $30.52, high $96.10) — a potential gain of +422% on today's $10.10. Buyers look set to stay in control over this stretch.
In 2040, ARTV is projected to trade between $34.22 and $132.91, averaging $67.06 — a potential gain of +564% from today's $10.10. That is up +27% on the projected 2035 average. Momentum favours further upside here.
Artiva Biotherapeutics, Inc.'s 2050 outlook centres on $192.58, within a $86.66 to $429.41 range. That is up +187% on the projected 2040 average. That marks a +18.1x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ARTV today (≈ 99.009901 ARTV) could be worth
$19,067.54
+$18,067.54 (+1807%) by 2050 · US Dollar
Based on the average projected ARTV price of $192.58 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARTVwould be worth at today's price.
$1,000 invested in ARTV on Jul 31, 2025 (≈ 333.333333 ARTV) would be worth
$3,366.67
+$2,366.67 (+236.7%) today · 3.37× · US Dollar
Based on a ARTV entry price of $3 vs. today's $10.1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.03 | $1,006.98 | +0.7% |
| 1 month ago | $9.8 | $1,030.61 | +3.1% |
| 3 months ago | $10.8 | $935.19 | -6.5% |
| 6 months ago | $4.18 | $2,416.27 | +141.6% |
| 1 year ago | $3 | $3,366.67 | +236.7% |
| All time (2.0y) ago | $12 | $841.67 | -15.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARTV forecast.
Our base-case forecast reaches $20.00 around 2028.
Implied market cap at $20.00: $971.76M
The multi-year forecast shows sustained upside, with 2030 forecast averages and ROIs indicating strong positive movement. For 2030, the min is $15.58, the avg is $23.88, the max is $39.57, with an ROI of 131.4% and bullish sentiment. The 2040 forecast projects a min of $26.84, an avg of $56.24, a max of $115.73, and an ROI of 445% with bullish sentiment.
The 2050 forecast shows a min of $71.66, an avg of $159.25, a max of $366.28, and an ROI of 1443.1% with bullish sentiment. These figures illustrate substantial upside over the long run, though they are estimates and not guarantees.
Tap a question to reveal the answer.
2030 min $15.58, avg $23.88, max $39.57; ROI 131.4%; sentiment bullish.
Forecasts show bullish sentiment across several years with rising averages and positive ROIs (e.g., 2027 avg $14.42, ROI 39.7%; 2028 avg $21.38, ROI 107.2%; 2029 avg $24.50, ROI 137.4%; 2030 avg $23.88, ROI 131.4%). These are estimates, not guarantees.
Yes, the 2040 max is $115.73, which would exceed $100. The 2040 min is $26.84 and the average is $56.24.
$7.60 to $14.01.
Current price $10.32; Market cap $501.43M.
Artiva Biotherapeutics, Inc. Community Discussion
0Share your Artiva Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.